Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | ITGAV | P06756 | 3/20 | 0.35 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.35 |
| ▸ | TGM2 | P21980 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CPB2 | Q96IY4 | 4/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | ITGB6 | P18564 | 2/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4257792 | 0.85 | HDAC4 (0.49) | HDAC4HDAC1EPHX1CASP1ITGAV | |
| SCHEMBL4257798 | 0.85 | HDAC4 (0.49) | HDAC4HDAC1EPHX1CASP1ITGAV | |
| SCHEMBL1445009 | 0.84 | HDAC4 (0.51) | HDAC4HDAC1EPHX1CASP1ITGAV | |
| SCHEMBL2812234 | 0.84 | HDAC4 (0.51) | HDAC4HDAC1EPHX1CASP1ITGAV | |
| SCHEMBL8233643 | 0.80 | EPHX1 (0.45) | HDAC4HDAC1EPHX1CASP1ITGAV | |
| SCHEMBL22777304 | 0.79 | EPHX1 (0.51) | HDAC4HDAC1EPHX1ITGAVITGB3 | |
| SCHEMBL5740541 | 0.78 | HDAC4 (0.54) | HDAC4HDAC1EPHX1CASP1ITGAV | |
| SCHEMBL28263995 | 0.78 | HDAC4 (0.52) | HDAC4HDAC1EPHX1CPB2 | |
| SCHEMBL454654 | 0.78 | HDAC4 (0.52) | HDAC4HDAC1EPHX1CPB2 | |
| SCHEMBL1645916 | 0.77 | SMN1; SMN2 (0.45) | HDAC4HDAC1ITGAVITGB3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8674088-B2 | Antiviral phosphinate compounds | GILEAD SCIENCES, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8586744-B2 | Antiviral phosphinate compounds | GILEAD SCIENCES, INC. (US) | 2013-11-19 | — | — | US | disclosed |
| EP-2043658-B1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES INC (US) | 2012-04-25 | — | — | EP | disclosed |
| EP-2422791-A1 | Antiviral phosphinate compounds | Gilead Sciences, Inc. (US) | 2012-02-29 | — | — | EP | disclosed |
| US-20110081314-A1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| US-20110082112-A1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| US-7893264-B2 | viricides comprising phosphinic acid compounds and/or mixed with carriers, nucleoside analogues, interferons or pegylated interferons; treating hepatitis C or a hepatitis C associated disorders in animals; side effect reduction | GILEAD SCIENCES, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-20090227491-A1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2009-09-10 | — | — | US | disclosed |
| EP-2043658-A2 | ANTIVIRAL PHOSPHINATE COMPOUNDS | Gilead Sciences, Inc. (US) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008005565-A9 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES INC (US) | 2009-01-29 | — | — | WO | disclosed |
| US-20080057031-A1 | Antiviral phosphinate compounds | GILEAD SCIENCES, INC. (US) | 2008-03-06 | — | — | US | disclosed |
| WO-2008005565-A2 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080057031-A1 | Antiviral phosphinate compounds | PHOSPHO1, MAVS, ITPA | HDAC4 1551/4885HDAC1 1846/4885EPHX1 3290/4885 |
| US-20090227491-A1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | PHOSPHO1, MAVS, ITPA | HDAC4 1551/4885HDAC1 1846/4885EPHX1 3290/4885 |
| US-20110081314-A1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | PHOSPHO1, MAVS, ITPA | HDAC4 1551/4885HDAC1 1846/4885EPHX1 3290/4885 |
| US-20110082112-A1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | HAVCR2, PHOSPHO1, EIF2AK2 | HDAC4 1505/4885HDAC1 1535/4885EPHX1 3170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.